Back to Search
KATHERINE MATTHAY, M.D.
M.D.
Pediatrics Physician
NPI: 1801822499Individual
Specialties, Licenses & Credentials
Hematology (Internal Medicine) Physician
Internal Medicine — Hematology
Code: 207RH0000X
G33559(CA)
Pediatrics PhysicianPrimary
Pediatrics
Code: 208000000X
G33559(CA)
Research & Publications (20)
Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study.
PMID 19171716·J Clin Oncol·2009
4-observational
Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study.
PMID 19171714·J Clin Oncol·2009
3-trial
Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.
PMID 17369569·J Clin Oncol·2007
3-trial
Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.
PMID 16421427·J Clin Oncol·2006
3-trial
Is liver metastasis in neuroblastoma an indication for treatment reduction?
PMID 16261577·Pediatr Blood Cancer·2006
8-other
Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004.
PMID 15922508·Cancer Lett·2005
6-review
Central nervous system metastases in neuroblastoma: radiologic, clinical, and biologic features in 23 patients.
PMID 12833468·Cancer·2003
8-other
Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma.
PMID 12829667·J Clin Oncol·2003
8-other
Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.
PMID 11696644·J Nucl Med·2001
3-trial
Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force.
PMID 19401690·Br J Cancer·2009
4-observational
Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma.
PMID 19636009·J Clin Oncol·2009
3-trial
Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study.
PMID 19020877·Cancer Chemother Pharmacol·2009
8-other
Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study.
PMID 19171709·J Clin Oncol·2009
3-trial
The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report.
PMID 19047290·J Clin Oncol·2009
8-other
The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.
PMID 19047291·J Clin Oncol·2009
8-other
Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group.
PMID 19047298·J Clin Oncol·2009
3-trial
Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database.
PMID 19047282·J Clin Oncol·2009
8-other
Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG.
PMID 19530234·Pediatr Blood Cancer·2009
8-other
Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group.
PMID 18937318·Pediatr Blood Cancer·2009
3-trial
Successful treatment of high risk and recurrent pediatric desmoids using radiation as a component of multimodality therapy.
PMID 19410386·Int J Radiat Oncol Biol Phys·2009
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 505 PARNASSUS AVE, BOX 0106
SAN FRANCISCO, CA 94143 - Phone
- (415) 476-3831
Quick Facts
- NPI
- 1801822499
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile